CalciMedica is trading 6.5% down at $1.44 on October 6, 2026, with no new company-specific announcement clearly explaining the decline. - A September 30 prospectus supplement enables up to $25 million in sales through an existing at-the-market stock program. It could raise dilution concerns, but its connection to the decline is not established. - Supplied sector context reports biotech weakness, while broad market indexes are higher.